Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.33 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625772 | 0.97 | ALDH1A1 (0.36) | ALDH1A1LMNANTRK1NTRK2TRPM8 | |
| SCHEMBL6714655 | 0.89 | PTGER4 (0.38) | ALDH1A1NTRK1NTRK2TRPM8MEN1 | |
| SCHEMBL6710720 | 0.88 | PTGER4 (0.39) | ALDH1A1NTRK1NTRK2TRPM8MEN1 | |
| SCHEMBL6715058 | 0.88 | NPC1 (0.37) | TRPM8CXCR3 | |
| SCHEMBL1625686 | 0.87 | NTRK1 (0.35) | NTRK1NTRK2TRPM8KMT2APDE10A | |
| SCHEMBL1625340 | 0.86 | NTRK1 (0.36) | NTRK1NTRK2TRPM8PDE10ATP53 | |
| SCHEMBL1623978 | 0.86 | TBXAS1 (0.35) | ALDH1A1NTRK1NTRK2TRPM8CXCR3 | |
| SCHEMBL1623250 | 0.85 | PTGER4 (0.41) | NTRK1NTRK2TRPM8 | |
| SCHEMBL1624796 | 0.85 | NPC1 (0.39) | ALDH1A1LMNATRPM8 | |
| SCHEMBL6713167 | 0.84 | PTGER4 (0.41) | ALDH1A1NTRK1NTRK2TRPM8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | ALDH1A1 1858/4885LMNA 3215/4885NTRK1 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.